Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients
Primary Purpose
Hemophilia
Status
Completed
Phase
Phase 4
Locations
Thailand
Study Type
Interventional
Intervention
combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Sponsored by
About this trial
This is an interventional supportive care trial for Hemophilia
Eligibility Criteria
Inclusion Criteria: Severe Hemophilia A patients Exclusion Criteria: -
Sites / Locations
- King Chulalongkorn Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities
PK-guided EHL FVIII concentrates prophylaxis alone
Arm Description
PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities
PK-guided EHL FVIII concentrates prophylaxis alone
Outcomes
Primary Outcome Measures
annualized bleeding rates (ABR)
annualized bleeding rates (ABR)
annualized joint bleeding rates (AJBR)
annualized joint bleeding rates (AJBR)
haemophilia-specific quality-of-life (Haemo-QoL-A) scores
haemophilia-specific quality-of-life (Haemo-QoL-A) scores
hemophilia Joint Health Scores (HJHS)
hemophilia Joint Health Scores (HJHS)
Secondary Outcome Measures
Full Information
NCT ID
NCT05728528
First Posted
December 28, 2022
Last Updated
February 5, 2023
Sponsor
Chulalongkorn University
1. Study Identification
Unique Protocol Identification Number
NCT05728528
Brief Title
Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients
Official Title
Impact of Moderate to Vigorous-intensity Physical Activities on Pharmacokinetic-guided Extended Half-life FVIII Concentrates Prophylaxis Severe Hemophilia A Patients
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
July 1, 2022 (Actual)
Primary Completion Date
December 31, 2022 (Actual)
Study Completion Date
December 31, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chulalongkorn University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To compare clinical outcomes before and after using combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis in moderate to severe hemophilia A patients
Detailed Description
This is a prospective cohort study of severe hemophilia A patients receiving low-dose EHL FVIII concentrates with PK-guided EHL FVIII concentrates prophylaxis alone for 6 months. Additional exercise workshops from sport scientists were introduced individually to this group of patients along with using the same prophylaxis method for another period of 6 months. The annualized bleeding rates (ABR), the annualized joint bleeding rates (AJBR), the haemophilia-specific quality-of-life (Haemo-QoL-A) scores, the hemophilia Joint Health Scores (HJHS) and skeletal muscle mass were compared between these two periods
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemophilia
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
13 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities
Arm Type
Experimental
Arm Description
PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities
Arm Title
PK-guided EHL FVIII concentrates prophylaxis alone
Arm Type
Active Comparator
Arm Description
PK-guided EHL FVIII concentrates prophylaxis alone
Intervention Type
Drug
Intervention Name(s)
combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
Intervention Description
combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
Intervention Type
Drug
Intervention Name(s)
pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Intervention Description
pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Primary Outcome Measure Information:
Title
annualized bleeding rates (ABR)
Description
annualized bleeding rates (ABR)
Time Frame
6 months
Title
annualized joint bleeding rates (AJBR)
Description
annualized joint bleeding rates (AJBR)
Time Frame
6 months
Title
haemophilia-specific quality-of-life (Haemo-QoL-A) scores
Description
haemophilia-specific quality-of-life (Haemo-QoL-A) scores
Time Frame
6 months
Title
hemophilia Joint Health Scores (HJHS)
Description
hemophilia Joint Health Scores (HJHS)
Time Frame
6 months
10. Eligibility
Sex
Male
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Severe Hemophilia A patients
Exclusion Criteria:
-
Facility Information:
Facility Name
King Chulalongkorn Memorial Hospital
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients
We'll reach out to this number within 24 hrs